Sucralose revisited: Rebuttal of two papers about Splenda safety

Regulatory Toxicology and Pharmacology

Volumn 63, Issue 3, 2012, Pages 505-508

  Schiffman, Susan S ^a   Abou Donia, Mohamed B ^b  

^a Duke University Medical Center ^*  (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D1; CYTOCHROME P450 3A4; MULTIDRUG RESISTANCE PROTEIN; SUCRALOSE;

AEROBIC BACTERIUM; ANAEROBE; BACTERIAL COUNT; BACTEROIDES; BIFIDOBACTERIUM; CLOSTRIDIA; COLON; CONCENTRATION RESPONSE; ENTEROBACTERIACEAE; ENZYME INDUCTION; LACTOBACILLUS; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; PH; PRIORITY JOURNAL; PRODUCT SAFETY; PROTEIN EXPRESSION; TEMPERATURE; THIN LAYER CHROMATOGRAPHY; WEIGHT GAIN;

EID: 84863876028     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2012.05.002     Document Type: Letter

References (36)

1. Abou-Donia M.B., El-Masry E.M., Abdel-Rahman A.A., McLendon R.E., Schiffman S.S. Splenda alters gut microflora and increases intestinal P-glycoprotein and cytochrome P-450 in male rats. J. Toxicol. Environ. Health A 2008, 71:1415-1429.
2. Bannach G., Almeida R.R., Lacerda L.G., Schnitzler E., Ionashiro M. Thermal stability and thermal decomposition of sucralose. Eclet. Quím. São Paulo 2009, 34(4):21-26.
3. Barndt R.L., Jackson G. Stability of sucralose in baked goods. Food Technol. 1990, 44(1):62-66.
4. Benet L.Z. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm. 2009, 6:1631-1643.
5. Benet L.Z., Cummins C.L. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev. 2001, 50(Suppl 1):S3-S11.
6. Brusick D., Borzelleca J.F., Gallo M., Williams G., Kille J., Hayes A.W., Pi-Sunyer F.X., Williams C., Burks W. Expert panel report on a study of Splenda in male rats. Regul. Toxicol. Pharmacol. 2009, 55:6-12.
7. Deferme S., Augustijns P. The effect of food components on the absorption of P-gp substrates: a review. J. Pharm. Pharmacol. 2003, 55:153-162.
8. Dürr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., Fattinger K. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 2000, 68:598-604.
9. Eckford P.D., Sharom F.J. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J. 2005, 389(Pt 2):517-526.
10. Eckford P.D., Sharom F.J. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 2008, 47:13686-13698.
11. EU (European Union), 2004. Directive 2003/115/EC of the European Parliament and of the Council of 22 December 2003 amending Directive 94/35/EC on sweeteners for use in foodstuffs. Off. J. Eur. Union 47 (L24), pp. 65-71. http://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2004:024:SOM:en:HTML.
12. Gill H.S., Rutherfurd K.J., Cross M.L., Gopal P.K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am. J. Clin. Nutr. 2001, 74:833-839.
13. Gonzalez, F.J., Tukey, R.H., 2006. Drug Metabolism. In: Brunton, L.L., Lazo, J.S., Parker, K.L. (Eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed., McGraw-Hill, pp. 71-92 (Chapter 3).
14. Grotz V.L., Henry R.R., McGill J.B., Prince M.J., Shamoon H., Trout J.R., Pi-Sunyer F.X. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J. Am. Diet. Assoc. 2003, 103:1607-1612.
15. Grotz V.L., Munro I.C. An overview of the safety of sucralose. Regul. Toxicol. Pharmacol. 2009, 55:1-5.
16. Hawkins, D.R., Wood, S.W., Waller, A.R., Jordan, M.C., 1987. Enzyme induction studies of TGS and TGS-HP in the rat. Unpublished Report from Huntingdon Research Centre, Huntingdon, UK. Submitted to the World Health Organization by Tate & Lyle. Cited In: JECFA, 1989 http://www.inchem.org/documents/jecfa/jecmono/v024je05.htm.
17. Hough L., Khan R. Intensification of sweetness. Trends Biochem. Sci. 1978, 3:61-63.
18. Hutchinson, S.A., 1996. Ph.D. dissertation. Rutgers University, New Brunswick, New Jersey.
19. Hutchinson S.A., Ho G.S., Ho C.T. Stability and degradation of the high-intensity sweeteners: aspartame, alitame, and sucralose. Food Rev. Int. 1999, 15:249-261.
20. Labare M.P., Alexander M. Microbial cometabolism of sucralose, a chlorinated disaccharide, in environmental samples. Appl. Microbiol. Biotechnol. 1994, 42:173-178.
21. Laurenzana E.M., Sorrels S.L., Owens S.M. Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6. Drug Metab. Dispos. 1995, 23:271-278.
22. Li X., Du Z., Huang X., Yuan W., Ying H. Solubility of sucralose in different solvents from (283.15 to 333.15)K. J. Chem. Eng. Data 2010, 55:2600-2602.
23. Lown K.S., Kolars J.C., Thummel K.E., Barnett J.L., Kunze K.L., Wrighton S.A., Watkins P.B. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 1994, 22:947-955.
24. NIH (National Institutes of Health), 2011. Financial Conflicts of Interest. http://grants.nih.gov/grants/policy/coi/index.htm.
25. O'Flaherty S., Klaenhammer T.R. The role and potential of probiotic bacteria in the gut, and the communication between gut microflora and gut/host. Int. Dairy J. 2010, 20:262-268.
26. Rahn A., Yaylayan V.A. Thermal degradation of sucralose and its potential in generating chloropropanols in the presence of glycerol. Food Chem. 2010, 118:56-61.
27. Roberts A., Renwick A.G., Sims J., Snodin D.J. Sucralose metabolism and pharmacokinetics in man. Food Chem. Toxicol. 2000, 38(Suppl 2):S31-S41.
28. Ross R.P., Mills S., Hill C., Fitzgerald G.F., Stanton C. Specific metabolite production by gut microbiota as a basis for probiotic function. Int. Dairy J. 2010, 20:269-276.
29. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 1996, 49:311-318.
30. Sherman P.M., Ossa J.C., Johnson-Henry K. Unraveling mechanisms of action of probiotics. Nutr. Clin. Pract. 2009, 24:10-14.
31. Sims J., Roberts A., Daniel J.W., Renwick A.G. The metabolic fate of sucralose in rats. Food Chem. Toxicol. 2000, 38(Suppl 2):S115-S121.
32. US FDA (United States Food and Drug Administration), 1998. Food Additives Permitted for Direct Addition to Food for Human Consumption; Sucralose. 21CFR Part 172 [Docket No. 87F-0086]. Federal Register vol. 63(64), 1998, pp. 16417-16433. http://www.fda.gov/ohrms/dockets/98fr/040398a.pdf.
33. Villena J., Racedo S., Agüero G., Bru E., Medina M., Alvarez S. Lactobacillus casei improves resistance to pneumococcal respiratory infection in malnourished mice. J. Nutr. 2005, 135:1462-1469.
34. Wang E.J., Lew K., Casciano C.N., Clement R.P., Johnson W.W. Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother. 2002, 46:160-165.
35. Wang K.Y., Li S.N., Liu C.S., Perng D.S., Su Y.C., Wu D.C., Jan C.M., Lai C.H., Wang T.N., Wang W.M. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am. J. Clin. Nutr. 2004, 80:737-741.
36. Yaylayan, V., 2009. Molecular mechanism of 3-MCPD ester formation: facts and hypothesis. ILSI Europe Workshop on 3-MCPD Esters in Food Products. Brussels, Belgium, 2009. http://www.ilsi.org/europe/publications/final%20version%203%20mcpd%20esters.pdf.